DA Yardley

602 total citations
70 papers, 427 citations indexed

About

DA Yardley is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, DA Yardley has authored 70 papers receiving a total of 427 indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Oncology, 42 papers in Pulmonary and Respiratory Medicine and 30 papers in Cancer Research. Recurrent topics in DA Yardley's work include Cancer Treatment and Pharmacology (45 papers), Advanced Breast Cancer Therapies (37 papers) and Breast Cancer Treatment Studies (24 papers). DA Yardley is often cited by papers focused on Cancer Treatment and Pharmacology (45 papers), Advanced Breast Cancer Therapies (37 papers) and Breast Cancer Treatment Studies (24 papers). DA Yardley collaborates with scholars based in United States, Canada and France. DA Yardley's co-authors include Howard A. Burris, John D. Hainsworth, F. Anthony Greco, Véronique Dièras, Roohi Ismail‐Khan, David R. Spigel, Paula Klein, Robert C. Whorf, David Waterhouse and N. Davidson and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

DA Yardley

61 papers receiving 413 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
DA Yardley United States	10	324	166	158	133	56	70	427
K. L. Blackwell United States	7	311 1.0×	71 0.4×	103 0.7×	118 0.9×	93 1.7×	16	438
C. P. Carden United Kingdom	6	213 0.7×	139 0.8×	140 0.9×	104 0.8×	23 0.4×	8	358
Mariangela Zanghì Italy	7	234 0.7×	79 0.5×	211 1.3×	144 1.1×	40 0.7×	12	414
Mary-Ann Lindsay United States	5	487 1.5×	182 1.1×	151 1.0×	162 1.2×	203 3.6×	5	588
José Roberto Freitas Rossari Belgium	6	273 0.8×	157 0.9×	107 0.7×	68 0.5×	27 0.5×	8	329
Jean-Yves Leroy Belgium	6	396 1.2×	158 1.0×	49 0.3×	223 1.7×	104 1.9×	11	465
Nicolas Kiavué France	10	257 0.8×	179 1.1×	110 0.7×	110 0.8×	36 0.6×	13	363
David Hernández‐Barajas Mexico	8	135 0.4×	77 0.5×	157 1.0×	140 1.1×	25 0.4×	26	322
Tanja Badovinac-Črnjević United States	7	418 1.3×	120 0.7×	161 1.0×	68 0.5×	185 3.3×	9	533
Christopher Stokoe United States	9	480 1.5×	254 1.5×	134 0.8×	49 0.4×	189 3.4×	17	547

Countries citing papers authored by DA Yardley

Since Specialization

Citations

This map shows the geographic impact of DA Yardley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by DA Yardley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites DA Yardley more than expected).

Fields of papers citing papers by DA Yardley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by DA Yardley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by DA Yardley. The network helps show where DA Yardley may publish in the future.

Co-authorship network of co-authors of DA Yardley

This figure shows the co-authorship network connecting the top 25 collaborators of DA Yardley. A scholar is included among the top collaborators of DA Yardley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with DA Yardley. DA Yardley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stroyakovskiy, Daniil, DA Yardley, Chiun‐Sheng Huang, et al.. (2025). LBA14 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 5-year outcomes. Annals of Oncology. 36. S1559–S1559.

Sammons, Sarah, DA Yardley, Priyanka Sharma, et al.. (2025). Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2− Advanced Breast Cancer. Oncology and Therapy. 14(1). 19–25.

Fasching, Peter A., Dennis J. Slamon, Zbigniew Nowecki, et al.. (2025). Health-Related Quality of Life in Patients with HR+/HER2− Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial. Clinical Cancer Research. 31(9). 1625–1635. 2 indexed citations

Hurvitz, Sara A., Michał Jarząb, Montserrat Muñoz-Mateu, et al.. (2025). Abstract P4-09-22: Distant disease-free survival (DDFS) across key subgroups from the phase 3 NATALEE trial of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in patients with HR+/HER2− early breast cancer (EBC). Clinical Cancer Research. 31(12_Supplement). P4–9.

Tripathy, Debu, G. N. Hortobagyi, Arlene Chan, et al.. (2019). Pooled safety analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2– advanced breast cancer (ABC). Annals of Oncology. 30. iii53–iii53. 9 indexed citations

Chan, Arlene, S-A. Im, Stephen Chia, et al.. (2019). Abstract P6-18-15: Ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis. Cancer Research. 79(4_Supplement). P6–18.

O’Shaughnessy, Joyce, A. DeMichele, X. Cynthia, et al.. (2017). Abstract P4-22-04: A randomized, double-blind, phase 2 study of ruxolitinib (RUX) or placebo (PBO) in combination with capecitabine (CAPE) in patients (pts) with advanced HER2-negative breast cancer (ABC) and elevated C-reactive protein (CRP), a marker of systemic inflammation. Cancer Research. 77(4_Supplement). P4–22. 1 indexed citations

Verma, Sunil, Sara A. Hurvitz, Ian E. Krop, et al.. (2016). HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and T-DM1. Annals of Oncology. 27. vi99–vi99.

Melisko, Michelle, DA Yardley, Kimberly Blackwell, et al.. (2016). Abstract OT1-03-15: The METRIC trial: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC). Cancer Research. 76(4_Supplement). OT1–3. 2 indexed citations

10.

Yardley, DA, et al.. (2016). Abstract P5-14-04: A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic breast cancer: Interim analysis. Cancer Research. 76(4_Supplement). P5–14. 4 indexed citations

11.

Yardley, DA, Adam Brufsky, Pierfranco Conté, et al.. (2013). Abstract OT3-1-11: tnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer. Cancer Research. 73(24_Supplement). OT3–1. 3 indexed citations

12.

Burris, H.A., Michael Gnant, G. N. Hortobágyi, et al.. (2013). Abstract P2-16-17: Characterization of response to everolimus (EVE) in BOLERO-2: A phase 3 trial of EVE plus exemestane (EXE) in postmenopausal women with HR+, HER2- advanced breast cancer. Cancer Research. 73(24_Supplement). P2–16. 2 indexed citations

13.

Tolaney, SM, DA Yardley, Beverly Moy, et al.. (2013). Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). Cancer Research. 73(24_Supplement). S1–4. 22 indexed citations

14.

Crown, John, Véronique Dièras, Elżbieta Starosławska, et al.. (2010). Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC).. Journal of Clinical Oncology. 28(18_suppl). LBA1011–LBA1011. 56 indexed citations

15.

Barton, John H., Dianna Shipley, Edward Arrowsmith, et al.. (2009). Efficacy results from a multicenter phase II noncomparative two-arm pilot trial of bevacizumab with anastrozole or fulvestrant as first-line endocrine therapy for metastatic breast cancer. Journal of Clinical Oncology. 27(15_suppl). 1091–1091. 5 indexed citations

16.

Yardley, DA, et al.. (2009). Rheumatologic Evaluation of Adjuvant Letrozole in Post-Menopausal Breast Cancer Patients Discontinuing Anastrozole Due to Grade 2-3 Arthralgia – Myalgia.. Cancer Research. 69(24_Supplement). 805–805. 5 indexed citations

17.

Yardley, DA, et al.. (2009). Final results of a first line multicenter phase II metastatic breast cancer trial of vinflunine monotherapy and in combination with trastuzumab in HER2+ patients.. Cancer Research. 69(2_Supplement). 3148–3148. 3 indexed citations

18.

Tripathy, Debu, Peter A. Kaufman, Adam Brufsky, et al.. (2009). registHER: Treatment outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR+) metastatic breast cancer (MBC). Journal of Clinical Oncology. 27(15_suppl). 1057–1057. 1 indexed citations

19.

Raefsky, Eric, Dana S. Thompson, Chun Meng, et al.. (2008). Phase II study of neoadjuvant bevacizumab and trastuzumab administered with albumin-bound paclitaxel (nab paclitaxel) and carboplatin in HER2+ locally advanced breast cancer. Journal of Clinical Oncology. 26(15_suppl). 627–627. 11 indexed citations

20.

Peacock, N. W., James D. Bearden, F. Anthony Greco, et al.. (2005). Phase II trial of gemcitabine plus trastuzumab in minimally pretreated HER2 overexpressing metastatic breast cancer. Journal of Clinical Oncology. 23(16_suppl). 704–704. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact